Breast cancer liquid biopsy market set to reach $1.9 billion by 2032

From GlobeNewswire: 2025-01-06 04:00:00

The breast cancer liquid biopsy market reached USD 305.9 million in 2023, projected to grow at a CAGR of 22.6% from 2024 to 2032. Innovations like next-generation sequencing are driving this growth, offering accurate and minimally invasive methods for early detection and personalized treatment. Increased awareness of genetic risks is also boosting demand for these technologies.

Segmented by biomarker type, the cfDNA segment is expected to maintain a strong CAGR of 22.5% in 2023. cfDNA’s ability to reveal real-time tumor dynamics and detect emerging mutations linked to drug resistance makes it a popular choice for early detection and personalized treatment plans. Kits & reagents hold a significant 67.1% share in the market, facilitating non-invasive diagnostic procedures for breast cancer.

North America led the breast cancer liquid biopsy market in 2023 with a valuation of USD 133.3 million. The region’s advanced healthcare infrastructure and significant R&D investments drive the adoption of liquid biopsy technologies as non-invasive alternatives to traditional methods. The market is expected to grow globally, driven by innovative technologies and a focus on patient-specific treatment strategies.

Major players in the breast cancer liquid biopsy market include Datar Cancer Genetics, Epic Sciences, F. Hoffmann-La Roche, Genes2me, Illumina, and more. The market’s growth is fueled by advancements in technology, early cancer detection efforts, and a shift towards minimally invasive diagnostic techniques. This expansion underscores the importance of accurate and patient-specific treatment strategies in cancer care.



Read more at GlobeNewswire: Breast Cancer Liquid Biopsy Market to hit USD 1.9 billion